

A cellular disease model toward gene therapy of *TGM1*-dependent lamellar ichthyosis

Laura Sercia,¹ Oriana Romano,² Grazia Marini,¹ Elena Enzo,¹ Mattia Forcato,² Laura De Rosa,^{1,3} and Michele De Luca^{1,3}

¹Center for Regenerative Medicine “Stefano Ferrari”, Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy; ²Department of Molecular Medicine, University of Padova, 35131 Padova, Italy

Lamellar ichthyosis (LI) is a chronic disease, mostly caused by mutations in the *TGM1* gene, marked by impaired skin barrier formation. No definitive therapies are available, and current treatments aim at symptomatic relief. LI mouse models often fail to faithfully replicate the clinical and histopathological features of human skin conditions. To develop advanced therapeutic approaches, such as combined *ex vivo* cell and gene therapy, we established a human cellular model of LI by efficient CRISPR-Cas9-mediated gene ablation of the *TGM1* gene in human primary clonogenic keratinocytes. Gene-edited cells showed complete absence of transglutaminase 1 (TG1) expression and recapitulated a hyperkeratotic phenotype with most of the molecular hallmarks of LI *in vitro*. Using a self-inactivating γ -retroviral (SIN γ -RV) vector expressing transgenic *TGM1* under the control of its own promoter, we tested an *ex vivo* gene therapy approach and validate the model of LI as a platform for pre-clinical evaluation studies. Gene-corrected *TGM1*-null keratinocytes displayed proper TG1 expression, enzymatic activity, and cornified envelope formation and, hence, restored proper epidermal architecture. Single-cell multiomics analysis demonstrated proviral integrations in holoclone-forming epidermal stem cells, which are crucial for epidermal regeneration. This study serves as a proof of concept for assessing the potential of this therapeutic approach in treating *TGM1*-dependent LI.

INTRODUCTION

Lamellar ichthyosis (LI) is one of the most common forms of autosomal recessive congenital ichthyoses (ARCI), a heterogeneous group of keratinization disorders mainly characterized by abnormal skin scaling over the whole body.^{1,2} Over 30% of LI is caused by mutations in *TGM1*,^{3,4} the gene encoding transglutaminase 1 (TG1), a 90-kDa, membrane-bound, calcium-dependent enzyme that catalyzes the formation of N ϵ -(γ -glutamyl)lysine bonds between (and within) proteins forming the cross-linked cornified cell envelopes (CEs) of the epidermis.^{5,6} Loss of TG1 function results in an impaired epidermal barrier, leading to transepidermal water loss and severe, often life-threatening, dehydration, especially during the first weeks of life.^{4,7}

LI is characterized by severe skin dryness, erythema, hyperkeratosis, and massive scaling, highly impairing patients' quality of life.^{8,9}

Affected individuals are often born with a “collodion membrane” that sheds in the first week of life, leaving patients with a disfiguring ichthyosis, characterized by coarse and dark-brown scales.^{7,10} LI is commonly associated with ectropion and eclabium (reversal of the eyelids and lips because of tension from the collodion membrane) and scarring alopecia. Flexural surfaces and palms and soles are frequently involved.^{8,11} Depending on *TGM1* mutations, LI can range from very mild to severe forms,^{12,13} with variable degrees of scaling, hyperkeratosis, and erythema, all of which require different approaches and even personalized therapies.

Currently, treatments for most ARCI are not tailored, and patients lack definitive therapeutic options.^{14,15} Enzyme replacement therapy (ERT) with nanoparticles and liposomes or non-integrating herpes simplex virus aim at skin-topical delivery of human recombinant TG1.^{16–18} Non-viral gene transfer techniques have been also exploited for *TGM1* gene delivery in organotypic cultures from LI patients' keratinocytes with the adenovirus-enhanced, transferrin-receptor-mediated transfection (AVET) system.¹⁹ However, AVET transfection did not show the expected efficiency in primary keratinocytes, which could be due to the presence of a stratum corneum or the absence of a receptor for adenovirus entry.²⁰ The epidermis is a highly renewing tissue, and the administered proteins or the non-integrating viral vectors have a temporary therapeutic effect, making repeated—perhaps lifelong—applications necessary. Since most ichthyoses (including *TGM1*-LI) are chronic life-long diseases, there is an urgent need for safe, effective, and definitive therapies. The first *ex vivo* gene therapy approach envisaged the delivery of the *TGM1* gene into LI patient cells using an amphotropic retroviral vector or direct injection of naked DNA in a skin humanized mouse model.^{21–23} It was shown that, after *TGM1*-retrovirus transduction, the expression and activity

Received 24 May 2024; accepted 29 July 2024;
<https://doi.org/10.1016/j.omtm.2024.101311>.

³These authors contributed equally

Correspondence: Laura De Rosa, Center for Regenerative Medicine “Stefano Ferrari”, Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

E-mail: laura.derosa@unimore.it

Correspondence: Michele De Luca, Center for Regenerative Medicine “Stefano Ferrari”, Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.

E-mail: michele.deluca@unimore.it






Figure 1. Differentiation-related expression of EGFP in HaCaT cells transduced with SIN γ -RVs

(A) Top: schematic of self-inactivating γ -retroviral vectors (SIN γ -RVs) carrying the three different promoters that drive the expression of the bicistronic gene encoding EGFP and puromycin resistance. Bottom: graphic of the HaCaT differentiation protocol. (B) K10 (left) and endogenous TGM1 (ED TGM1) (right) relative mRNA expression in non-transduced (NT) and transduced (TGM1^{full}) HaCaT cells, grown in low calcium (t0) and high calcium for 1, 4, and 6 days. GAPDH mRNA was used to normalize the RT-PCR. (C) RT-qPCR quantification of the relative mRNA expression value of EGFP. GAPDH mRNA was used to normalize the RT-PCR ($p < 0.0001$). (D) Western blot analysis of EGFP expression in low-calcium (t0) and high-calcium culture conditions for 4 or 6 days of cultivation. NT HaCaT cells 6 days after calcium addition are loaded as a reference sample. t0: time zero.

of TG1 was restored in keratinocytes of LI patients *in vitro*.²¹ Although these data were relevant in showing the possibility of phenotypic correction of LI, these strategies have never reached clinical application.

Ex vivo combined cell and gene therapy has been successfully exploited in other recessively inherited genodermatoses, such as junctional and dystrophic epidermolysis bullosa.^{24–27} A functional copy of the defective gene can be introduced into the genome of clonogenic keratinocytes by means of replication-defective retroviral vectors. Cultured transgenic keratinocytes can then be used to prepare epidermal grafts able to permanently restore a functional epidermis.^{25,28} Notably, the long-term epidermal restoration strictly relies on the genetic modification of long-lived, self-renewing epidermal stem cells, detected as holoclone-forming cells.^{24,25}

Here we report a proof-of-concept study evaluating a combined cell and gene therapy approach aimed at correcting *TGM1* mutations underlying LI. A 3D *TGM1*-defective human cellular model was established and genetically corrected with a self-inactivating γ -retroviral (SIN γ -RV) vector expressing the *TGM1* cDNA under the control of its own promoter. This study confirms the valuable tool of the 3D human cellular model in replacing animal models and avoiding the need for patient biopsies and demonstrated the feasibility of a combined cell and gene therapy strategy for *TGM1*-LI disease.

RESULTS

Selecting promoters driving physiological *TGM1* expression in differentiated keratinocytes

Given the peculiar cross-linking, calcium-dependent enzymatic activity of TG1 and its location and function in distinct suprabasal epidermal layers,^{5,6,29} the selection of the appropriate promoter is a major step toward a successful gene therapy. To this end, SIN γ -RV vectors expressing enhanced green fluorescent protein (EGFP) under the control of three different promoters were produced. These include a 637-bp human involucrin minimal promoter (IVL^{min}), a 367-bp human *TGM1* minimal promoter (TGM1^{min}), and 2.2-kb human *TGM1* full-length promoter (TGM1^{full}) (Figure 1A, top). Such promoters were initially used to transduce HaCaT cells, a spontaneously immortalized human keratinocyte cell line expressing appropriate differentiation markers, a widely used model to study the balance between keratinocyte proliferation and differentiation upon changes in calcium concentration.^{30,31} As detailed in **materials and methods**, transgenic HaCaT cells were serially diluted to isolate a homogeneous EGFP⁺ cell population, which was then cultured in keratinocyte serum-free medium (KSFM) in 0.03 mM calcium (Ca^{2+low}) for at least 3 weeks and then switched to 2.8 mM calcium (Ca^{2+high}) to induce terminal differentiation (Figure 1A, bottom). Vector copy number evaluation (VCN) of transduced HaCaT clones was also performed (Figure S5). The expression of epidermis-specific differentiation markers (K10 and TGM1) progressively increases in Ca^{2+high} as compared to the basal level (time 0 [t0]), confirming proper differentiation stimuli also after transduction (Figure 1B). Ca²⁺ differentiation-dependent EGFP mRNA and protein expression were detected only with the TGM1^{full} promoter (Figures 1C and 1D). Time-resolved promoter activity was also investigated by live-cell imaging following Ca^{2+high}-induced terminal differentiation (Figure S1). EGFP was expressed in HaCaT cells transduced with TGM1^{min} and IVL^{min} promoters




Figure 2. The TGM1^{full} promoter drives EGFP expression in primary differentiated human keratinocytes

(A) Schematic of the *in vitro* keratinocyte differentiation experimental design. (B) Representative colony-forming efficiency (CFE) of keratinocyte cultures in growing (left) (d7) and over-confluent (right) culture conditions (d14). The number of cells per dish plated in the CFE condition is indicated in brackets. Colonies were stained with Rhodamine B after 12 days of cultivation. (C) Western blot analysis of keratinocyte differentiation markers (IVL, endogenous TG1, and K10) in growing (3-day), confluent (7- to 10-day), and over-confluent (14-day) normal, healthy keratinocytes (K82). (D) Western blot analysis of keratinocyte differentiation markers (IVL, endogenous TG1, and K10) and EGFP in growing (3-day), confluent (7- to 10-day), and over-confluent (14-day) K82 keratinocytes transduced with a SIN γ -RV carrying EGFP under the control of the TGM1^{full} promoter. (E) Progressive (3- to 14-day) increase of EGFP mRNA during transgenic keratinocyte differentiation and stratification. GAPDH mRNA was used to normalize the RT-qPCR (* $p < 0.0001$). (F) Representative immunofluorescence images of 7- μ m-thick cryosections of 3D SEs obtained with TGM1^{full} promoter-transduced keratinocytes, showing the expression of differentiation markers (endogenous TG1 and LEKT1) in the upper layers of the epidermis and collagen XVII and KRT14 as markers of the epidermal basal layer ($n = 3$, pictures are representative of what was observed in at least three independent samples or replicates). The EGFP fluorescent signal is properly restricted to the granular layer of the epidermis. White arrows indicate the presence of living fibroblasts inside the collagen matrix, expressing vimentin. A white dotted line marks the epidermal-dermal junction. DAPI (blue) stains nuclei. Scale bars, 20 μ m. LEKT1, lympho-epithelial Kazal-type-related inhibitor; KRT14, cytokeratin 14; VIM, vimentin.

independently of calcium-induced terminal differentiation. In sharp contrast, the TGM1^{full} promoter induced EGFP expression from day 5 after switching to Ca²⁺_{high} and progressively increased its activity during terminal differentiation, confirming that only the full promoter is properly regulated by differentiation stimuli.

TGM1^{full} promoter-driven expression of EGFP in primary human keratinocytes

Under appropriate culture conditions, primary human clonogenic keratinocytes give rise to colonies eventually generating cohesive epidermal sheets resembling the epidermis, which are routinely used in clinical settings for regenerative medicine.^{32,33} Keratinocyte confluence and initial stratification induce commitment to terminal differentiation, as demonstrated by the decrease of keratinocyte clonogenicity (Figures 2A and 2B)³⁴ and induction of early differentia-

tion markers, such as suprabasal keratin 10 and involucrin (Figure 2C).³⁵

To investigate the ability of the TGM1^{full} promoter to properly drive EGFP expression in primary human epidermal cells, keratinocytes were transduced with the SIN γ -RV-EGFP vectors previously used on HaCaT cells. The percentage of EGFP⁺ colonies was approximately 60%. Transduced keratinocytes were exposed to 2 μ g/mL puromycin to purify a homogeneous population of EGFP⁺ cells. VCN evaluation of transduced keratinocytes was also performed (Figure S5). The proper activation of the TGM1^{full} promoter was evaluated in growing, confluent, and over-confluent transgenic primary cultures (Figures 2 and S2). As investigated previously in HaCaT cells, primary human keratinocytes also displayed differences in the expression of the reporter gene among the three different promoters




Figure 3. Generation of the $\Delta TGM1$ human cellular model

(A) *TGM1* KO strategy design. gRNA1 and gRNA2 target E2, while gRNA3 targets E4 of the *TGM1* gene. gRNA1 and gRNA2 differ in 1 nt (underlined), allowing targeting of both alleles, exploiting the presence of a SNP in a wild-type strain (K81). gRNA sequences are enclosed in colored boxes, with the protospacer adjacent motif (PAM) shown in bold. (B) PCR analysis on both edited exons performed on genomic DNA from wild-type keratinocytes (K81) and $\Delta TGM1$ -nucleofected keratinocytes. Note the intensity reduction of the bands at 608 bp and 780 bp in $\Delta TGM1$ nucleofected keratinocytes. (C and D) RT-qPCR (C) and western blot analysis (D) show ablation of both TGM1 mRNA (C, orange bars) and protein (D) in $\Delta TGM1$ keratinocytes as compared to wild-type cells. (E) Relative TG1 enzymatic activity in growing (3-day) and over-confluent (14-day) wild-type and $\Delta TGM1$ keratinocytes. $n = 3$ replicates, data are presented as mean \pm SD (* $p < 0.0001$).

following differentiation stimuli. As shown in Figures 2D and 2E, transgenic keratinocytes transduced with the *TGM1*^{full} promoter showed the expected progressive, density-dependent increase of EGFP, mirroring the expression of endogenous TG1, hence confirming that only the activation of this promoter is finely controlled during epidermal differentiation. EGFP⁺ keratinocytes were then used to generate three-dimensional skin-equivalent (SE) cultures. To this end, transgenic keratinocytes were seeded onto a collagen matrix containing living fibroblasts and cultured for 1 week in submerged culture and then for 3 weeks in an air-liquid interface, allowing them to stratify and fully differentiate. Cultures were fixed and sectioned to examine morphology, differentiation markers, as well as EGFP protein expression in a biomimetic and physiological environment. A fully developed epidermis was obtained (Figure 2F). Differentiation markers, such as TG1 and LEKTI, were correctly localized and expressed in the upper layers of differentiated epidermis, while KRT14 and collagen XVII were correctly restricted to the epidermal basal layer (Figure 2F). EGFP fluorescence, visualized directly in sections, reflects the accumulation of EGFP signal only in the differentiated compartment when keratinocytes are transduced with both the

TGM1^{full} and *IVL*^{min} promoters (Figures 2F, bottom right, and S2C). Moreover, fibroblasts contained within the 3D SE clearly expressed vimentin, which indicates their viability, crucial for the maintenance of the 3D SE model.

These data demonstrate that retroviral vectors containing *TGM1*^{full} promoter can drive the expression of a reporter gene to the upper differentiated layers of the epidermis.

Generation of the $\Delta TGM1$ human cellular model

To create a reliable cellular model able to recapitulate the LI phenotype, *TGM1* was knocked out in primary keratinocyte cultures obtained from healthy donors using the CRISPR-Cas9 system. Three different CRISPR guide RNAs (gRNAs) were designed to target both *TGM1* alleles, exploiting the presence of a SNP in a wild-type strain (K81) (Figure 3A). gRNA1 and gRNA2 were designed to target exon 2 (E2) of the *TGM1* gene; these gRNAs differ for 1 nt close to the protospacer adjacent motif (PAM) sequence, which makes them allele specific. gRNA3 was designed to target exon 4 (E4). E2 and E4 were chosen for their crucial role in determining the protein function.

Indeed, E2 encodes for a unique TG1 N-terminal sequence that is required for membrane anchoring, while E4 encodes for a part of the catalytic core domain of the enzyme.^{29,36}

Human primary keratinocytes were nucleofected with ribonucleoprotein (RNP) complexes containing the three different gRNA-Cas9 pairs. In both exons, the corresponding edited sequences were assessed by PCR amplification of fragments spanning the target sites. Specific primers, designed on target sites, clearly showed virtually complete *TGM1* ablation (Figure 3B). Moreover, PCR amplification performed with primers spanning both the Cas9 target sites demonstrated that the excision of the entire genomic region (1.7 kb) between E2 and E4 is a high-frequency event (Figure S3A). Validation of efficient *TGM1* ablation was obtained by TIDE analysis through Sanger sequencing of E2 and E4, respectively, as compared to wild-type sequences. The overall editing efficiency, reaching 100%, is indicated by the absence of non-edited sequences (point 0 of the graphs) and the presence of a significant amount of insertions or deletions abolishing the open reading frame and expression of *TGM1* (Figure S3B).

TGM1 mRNA and TG1 protein expression, as well as TG1 enzymatic activity, tested both in growing (3-day) and high-density, differentiating (14-day) cultures, were undetectable in Δ *TGM1* keratinocytes as compared to wild-type keratinocytes (Figures 3C–3E). The remarkable efficacy of *TGM1* ablation achieved in bulk keratinocyte culture avoided the selection of specific clones of the keratinocytes treated with gRNA-Cas9 pairs.

Overall, these results demonstrate the feasibility and the high efficiency of *TGM1* knockout in human keratinocytes using the CRISPR-Cas9 system.

Δ TGM1 model for proof-of-concept therapy studies

Δ *TGM1* epidermal cells were transduced with a SIN γ -RV vector containing *TGM1* cDNA under the control of the *TGM1*^{full} promoter (SIN γ -RV-*TGM1*) (Figure S4A). Transgenic keratinocyte colonies clearly demonstrated the correct expression of exogenous TG1, closely resembling TG1 expression in normal keratinocyte colonies (Figure 4A).

In order to determine exogenous TG1 *in vitro* enzymatic function, its cross-linking activity was investigated in stratified keratinocytes cultures. During epidermal keratinization, TG1 catalyzes the formation of cross-linked cornified cell envelopes (CEs), which are chemically resistant to ionic detergent and reducing agent, as described previously.³⁷ Since the cross-linking process is strictly related to the presence of TG1 in terminally differentiated keratinocytes, the absence of a functional protein should result in failure to form CEs. Indeed, no CEs were detected in Δ *TGM1* keratinocytes, while typical polyhedral CEs were isolated both from normal and SIN γ -RV-*TGM1*-transduced keratinocytes (Figure 4B).

The ability to faithfully recapitulate the LI phenotype of the Δ *TGM1* keratinocytes was assessed in 3D SE models. SE models were prepared

using normal, Δ *TGM1*, or SIN γ -RV-*TGM1*-transduced (transgenic) keratinocytes. As shown in Figure 4C, top, TG1 protein expression in both normal and transgenic keratinocytes was correctly restricted to the granular layer with the typical pericellular distribution. Furthermore, the correct expression of exogenous TG1 in transgenic keratinocytes was associated with full restoration of its enzymatic activity (Figure 4C, bottom; red fluorescence indicates the *in situ* evaluation of TG1 enzymatic activity). Of note, Δ *TGM1* SE revealed an epidermis characterized by a thickened stratum corneum (SC) phenocopying the human ichthyosis phenotype.^{11,38,39} In contrast, the transgenic SE produced a normal SC virtually indistinguishable from that observed in SE models generated by wild-type keratinocytes (Figure 5).

The presence and spatial distribution of the TG1 substrates involucrin, LEKTI, and lorixin were also assessed (Figure 5). TG1 substrates showed a diffuse distribution in the Δ *TGM1* SE model with abnormal cytoplasmic staining, indicating the lack of protein cross-linking in the upper layers of the epidermis, as typically occurs in LI.^{40–42} In contrast, in the transgenic SE, each TG1 substrate is correctly localized at the cellular periphery of the upper differentiated layers of the epidermis, resembling the normal skin. The expression of K10, localized in the suprabasal cell layers, remained unchanged in all conditions.

Finally, gene-corrected *TGM1*-null keratinocytes examined at increased cell densities confirmed that exogenous TG1 protein expression is finely controlled during cell differentiation (Figure S4B), as proven by the expression of the involucrin differentiation marker.

Altogether, these findings demonstrated the restoration of TG1 expression and function using an *ex vivo* gene therapy approach mediated by a SIN γ -RV-*TGM1* vector in primary Δ *TGM1* keratinocytes, further corroborating the valuable established tool for testing novel therapies for LI.

Multiomics analysis of SIN γ -RV-*TGM1*-transduced keratinocytes

In view of a potential future clinical application of *TGM1*-transduced keratinocytes, it must be considered that long-term epidermal restoration strictly relies on the genetic modification of long-lived, self-renewing epidermal stem cells, detected as holoclone-forming cells.^{24,25} Since basal, clonogenic human keratinocytes, including stem cells, do not express *TGM1* mRNA, an assessment of exogenous *TGM1* expression cannot be performed solely by single-cell RNA sequencing (scRNA-seq) analysis. To this end, a single-keratinocyte multiomics analysis was conducted on SIN γ -RV-*TGM1*-transduced cells. This approach allowed for the simultaneous evaluation of provirus integration and transcriptome profiling within a single cell via scATAC-seq and scRNA-seq, respectively.

As shown in Figure 6A, transgenic keratinocytes contain the previously defined five keratinocyte populations,^{43,44} three of which are clonogenic (holoclone, meroclone, and paraclone), while the other two identify terminally differentiated cells (TD1 and TD2). The holoclone




Figure 4. SIN γ -RV-TGM1 rescues TG1 expression and activity in the $\Delta TGM1$ human cellular model

(A) Representative images of TG1 immunofluorescence analysis of wild-type, $\Delta TGM1$, and SIN γ -RV-TGM1-transduced keratinocytes after 7-days cultivation. DAPI (blue) stains nuclei. Scale bars, 50 μ m. (B) Optical micrographs of the isolated cornified cell envelopes in wild-type and SIN γ -RV-TGM1-transduced keratinocytes. Note that typical envelopes were not detected in $\Delta TGM1$ keratinocytes, and only a few cell fragments were observed. Scale bar, 20 μ m. (C) Immunostaining detection of TG1 protein (top, green) and TG1 *in situ* enzymatic activity (bottom, red) in cryosections of collagen-based 3D SEs from wild-type, $\Delta TGM1$, or SIN γ -RV-TGM1-transduced keratinocytes. DAPI (blue) stains nuclei. A white dotted line marks the epidermal-dermal junction. Scale bars, 50 μ m ($n = 3$, pictures are representative of what was observed in at least three independent samples or replicates).

population, formed by epidermal stem cells, is defined by the transcriptomic expression of a “holoclone signature”⁴³ (Figure S6A).

We were able to detect *TGM1*-proviral integration within individual cells by mapping scATAC-seq data of *TGM1*-transduced cells to a custom human reference genome that includes the sequence of the

SIN γ -RV-TGM1 provirus. About 30% of total cells were found to be positive for at least one exogenous *TGM1* fragment (Figures 6B and S6B), with the majority of them containing a unique proviral integration (Figures S6C and S5). Notably, a uniform distribution of *TGM1* proviral integration is found across all five keratinocytes populations (Figures 6B and S6B) without any clonal selection,




Figure 5. $\Delta TGM1$ 3D SEs resembling LI skin hallmarks and architecture

Histological analysis (H&E) and immunostaining of TG1 substrates (involucrin, LEKTI, and loricrin) and keratin 10 on 3D SEs from wild-type, $\Delta TGM1$, or SIN γ -RV- $TGM1$ -transduced keratinocytes. DAPI (blue) stains nuclei. A dotted line marks the epidermal-dermal junction. Scale bars, 20 μ m.




Figure 6. Single-cell multiomics analysis reveals *TGM1*-transduced keratinocyte stem cells

(A) UMAP of scRNA-seq profiles in SIN γ -RV-*TGM1*-transduced keratinocytes. Keratinocytes were classified in five clonogenic and differentiated populations through label transfer and mapping to a previously reported reference of human keratinocytes.^{43,44} Dots represent individual cells, and the colors indicate the cell populations (holoclone [H] in orange, meroclone [M] in light blue, paraclone [P] in gray, TD1 in light brown, and TD2 in brown). Feeder layer-derived fibroblasts and low-quality keratinocyte clusters (F1 and 6,7) are shown in light gray. The percentages of cells in each population are shown on the right. (B) UMAP showing SIN γ -RV-*TGM1*-positive cells containing at least one provirus fragment (red). The color scale indicates the number of provirus fragments retrieved in each cell. Negative cells are shown in light gray. The percentages of positive cells in each population are shown on the right.

demonstrating that the genetically corrected holoclones maintained their ability to self-renew *in vitro* and produce progenitors that replenish terminally differentiated keratinocytes.

These data clearly show that the proposed therapeutical strategy is able to preserve and genetically correct the population of epidermal stem cells, crucial for a possible *ex vivo* gene therapy approach aimed at full epidermal restoration.

DISCUSSION

TGM1-deficient LI is a rare cornification disorder associated with severe clinical complications that highly decrease the patient's quality of life.^{2,9,15} There is no cure for LI, and the existing treatments only aim at relieving the symptoms.^{45–47} Thus, there is a significant unmet need for therapeutic strategies aimed at correcting the *TGM1* deficiency underlying LI.^{48,49}

Currently, the most innovative therapeutical approaches (still not commercially available), are based on ERT^{16,17} or *in vivo* gene therapy¹⁸ (phase II clinical trial, KB105; [ClinicalTrials.gov: NCT05735158](https://clinicaltrials.gov/ct2/show/study/NCT05735158)). Although these therapeutical strategies are quite promising and technically feasible, they have a common drawback; namely, they could likely have only a temporary beneficial effect. Recently, an adenine base editing system has been proposed for the correction of a *TGM1* pathogenic mutation in human embryos.⁵⁰ Even though the goal of permanently correcting point mutations is admirable, it is important to consider the effectiveness of the process and to evaluate any possible off-target RNA occurrences. Additionally, the primary challenges associated with its clinical application include the high cost of precision medicine and the application of

this technology to human embryos. This latter aspect is the subject of constant debate.⁵¹

While γ -RV vectors, derived from the Moloney murine leukemia virus, are widely used in clinical trials for keratinocyte-based *ex vivo* gene therapy,^{52,53} they have the potential risk of insertional mutagenesis. To address this safety concern, SIN vectors lacking viral enhancers/promoters in their 3' long terminal repeat have been developed.^{54–56} These vectors mitigate the risk of insertional mutagenesis and provide the opportunity to utilize an internal, often tissue-specific promoter to elicit controlled and physiological expression of the target gene.^{54–56}

Combined *ex vivo* cell and gene therapy by means of cultured, autologous, transgenic keratinocytes can permanently restore a functional epidermis, as already shown with other devastating skin genetic diseases.^{24–27} In fact, combined *ex vivo* cell and gene therapy of generalized intermediate *LAMB3*-junctional epidermolysis bullosa (JEB) has proven to be life saving and able to permanently regenerate a fully functional epidermis in three JEB patients (up to 18 years of follow-up).^{25,28,57–59} But JEB is characterized by massive blisters and erosions (hence, by open wounds), allowing easier preparation of the dermal wound bed required for transplantation of the transgenic grafts. LI patients face an additional challenge, as their thickened SC must be surgically removed to expose the dermal layer. As a result, *ex vivo* gene therapy for LI patients becomes more invasive as compared to that for JEB patients. While it may initially seem daunting, *ex vivo* gene therapy treatments may improve the overall quality of life for LI patients affected by specific LI forms. For instance, localized *TGM1*-dependent bathing suit ichthyosis,^{7,60} which is characterized

by a distribution of lesions especially on the trunk, could be addressed first, providing an important proof of principle for the treatment of LI lesions.

The limited availability of patients with rare diseases and ethical concerns related to the need for tissue samples often hamper studies aimed at the development of this type of advanced therapies. Although LI murine models have been generated, *TGM1*^{-/-} mice exhibited an early lethality and poorly recapitulated the human phenotype.^{61,62} Our studies were conducted using an *in vitro* human LI model (*i*) allowing the cultivation of a fully differentiated human epidermis (*ii*) able to recapitulate the LI phenotype starting from keratinocytes obtained from surgical waste skin samples and (*iii*) allowing in-depth studies on molecular, biochemical, and functional restoration of TG1. More importantly, we provide evidence that long-lived self-renewing stem cells have been targeted and genetically corrected, thus maintaining the ability to permanently regenerate a functional epidermis. Such an experimental approach can not only avoid or limit animal experiments but, in the case of human skin diseases, also minimize the significant differences that exist between human and murine skin architecture and physiology. In fact, disease-resembling SEs models using the knockout (KO) strategy have been produced for other types of genodermatoses. For example, an effective cellular model of Netherton syndrome was developed by disrupting *SPINK5* through efficient CRISPR-Cas9-mediated gene ablation in human primary keratinocytes.⁶³ Both studies aim to develop surrogate models using human primary cells to investigate genodermatosis diseases that efficiently replicate the phenotype and molecular hallmarks of Netherton syndrome and *TGM1*-LI, respectively.

However, to achieve clinical application, two additional steps are required: (1) the development of a clinical-grade stable packaging cell line, which will enable high-titer, large-scale production of SIN γ -RVs, an essential step in transitioning from bench to bedside, and (2) the validation of these findings using LI patient-derived cells from multiple donors with diverse genetic backgrounds.

Taken together, these findings support the development of a human model for LI and pave the way for the prospective implementation of combined cell and gene therapy targeting at least specific forms of *TGM1*-dependent LI.

MATERIALS AND METHODS

Human tissues

All human tissues were collected after obtaining informed consent and in compliance with Italian regulations (Comitato Etico dell'Area Vasta Emilia Nord, number 178/09 for healthy donor skin samples).

Primary human cell cultures

Human skin samples were obtained as anonymized surgical waste, typically from abdominoplasty or mammoplasty. Briefly, skin biopsies were minced and trypsinized (0.05% trypsin/0.01% EDTA) at 37°C for 4 h. Cells were collected every 30 min, plated (2.5×10^4 /cm²) on lethally irradiated 3T3-J2 cells (2.4×10^4 /cm²),

and cultured in 5% CO₂ and a humidified atmosphere in keratinocyte growth medium (KGM): DMEM and Ham's F12 medium (3:1 mixture) containing fetal bovine serum (FBS) (10%), insulin (5 μ g/mL), adenine (0.18 mM), hydrocortisone (0.4 μ g/mL), cholera toxin (0.1 nM), triiodothyronine (liothyronine sodium) (2 nM), EGF (10 ng/mL), glutamine (4 mM), and penicillin-streptomycin (50 IU/mL).⁶⁴ Subconfluent primary cultures were serially propagated as described previously.^{43,65}

3T3-J2 cell line

Mouse 3T3-J2 cells were a gift from Prof. Howard Green (Harvard Medical School, Boston, MA, USA). Fibroblasts were cultivated in DMEM supplemented with 10% gamma-irradiated donor adult bovine serum, penicillin-streptomycin (50 IU/mL), and glutamine (4 mM).

HaCaT cell line

HaCaT cells, a spontaneously immortalized human keratinocyte line, were cultured in 5% CO₂ at 37°C in three different culture media as needed. Standard culture medium contained DMEM supplemented with 10% heat-inactivated FBS, glutamine (2 mM), and penicillin-streptomycin (100 IU/mL). Low-calcium medium contained KSM (17005042, Thermo Fisher Scientific) supplemented with 0.03 mM calcium chloride, 25 μ g/mL bovine pituitary extract (BPE; Thermo Fisher Scientific), 0.2 ng/mL of recombinant EGF (Thermo Fisher Scientific), and penicillin-streptomycin (100 IU/mL). High-calcium medium contained KSM supplemented with 2.8 mM of calcium chloride, 25 μ g/mL BPE, 0.2 ng/mL of recombinant EGF (Thermo Fisher Scientific), and penicillin-streptomycin (100 IU/mL).

Plasmid constructs and retrovirus production

Genomic DNA from human primary keratinocytes (K81) was used as template to generate (1i) *TGM1*^{min}, (2) *IVL*^{min}, and (3) *TGM1*^{full} by PCR using high-fidelity Taq polymerase (LA Taq DNA Polymerase, Takara). Specific primers were used to amplify the distal region (-1.6 kb/-1.4 kb) (containing the AP1 and Sp1 binding sites) and the proximal region (-90 bp/+67 bp) of the wild-type human *TGM1* promoter,⁶⁶ the distal region (-2.473 kb/-2.036 kb) and the proximal region (-221 bp/+6 bp) of the wild-type human involucrin promoter,⁶⁷ and the full-length (2.2 kb) human *TGM1* promoter. A list of PCR primers is shown in Table S1. The PCR fragments were verified by Sanger sequencing and subsequently cloned into SIN γ -RV HSC1-GiP, a gift from James Ellis (Addgene plasmid 58254), deprived of the internal human EF1 α promoter. The obtained constructs carry one of the three different promoters guiding the expression of a bicistronic cassette EGFP ires Puromycin. The HSC1-GiP vector was used as control. A retroviral vector expressing the full-length 2.9-kb *TGM1* cDNA (GeneArt, Invitrogen) was constructed by cloning the *TGM1* cDNA under the control of the *TGM1* full promoter into the HSC1-GiP backbone.

Phoenix-AMPHO cells were cultured in DMEM supplemented with 10% heat-inactivated FBS, 1% glutamine, and 1% penicillin-streptomycin antibiotics (Thermo Fisher Scientific). High-quality DNA of

each transfer vector was used for the transient transfection of Phoenix-AMPHO cells with branched high-performance polyethylenimine PEI (Sigma), for retroviral production. Infectious retroviruses were harvested 48 h post transfection, filtered through 0.45- μ m pore cellulose acetate filters, and concentrated by ultracentrifugation. Primary keratinocytes or HaCaT cells were infected with the retroviral stock at various multiplicities of infection (MOIs) with Vectofusin-1 (Miltenyi Biotec) or RetroNectin (Takara) addition.

Generation of genetically modified HaCaT cell cultures

HaCaT cells were transduced with SIN γ -RV-EGFP supernatants at MOI 5 with RetroNectin recombinant human fibronectin fragment solution (Takara; 20 μ g/mL in DPBS [Gibco]) at 10 μ g/cm². Each condition of SIN γ -RV-EGFP-transduced HaCaT cells was serially diluted (1 cell/well) for positive clone isolation. After 7 days of cultivation, fluorescent positive clones were selected using an inverted fluorescence microscope. EGFP⁺ clones were picked and expanded in serial passages. Transduced HaCaT cells were cultured in low-calcium conditions (0.03 mM Ca²⁺) for at least 3 weeks in order to induce a basal-like state that is characteristic of undifferentiated cells. HaCaT cells were then cultured in high-calcium conditions (2.8 mM Ca²⁺) to induce differentiation. Samples were harvested at t0 (low Ca²⁺) and 8 h, 24 h, 48 h, 4 days, and 6 days, after calcium addition.

Live-cell imaging of genetically modified HaCaT cell cultures

EGFP fluorescent emission of transduced HaCaT cells under differentiation conditions was evaluated with a Cell Observer microscope (Axio Observer Z1, 10 \times objective). Fluorescence and bright-field micrographs of the samples were acquired every 24 h for 6 days. Non-transduced HaCaT cells were used as a negative control.

Generation of genetically modified human primary keratinocytes

Sub-confluent keratinocytes mass cultures (K82) were treated with 0.05% trypsin and 0.01% EDTA for 15–20 min at 37°C and plated (3 \times 10⁴ cells/cm²) onto lethally irradiated 3T3-J2 cells (3 \times 10⁴ cells/cm²) in KGM without FBS or penicillin-streptomycin. SIN γ -RV-EGFP viral supernatants were added separately at MOI 1.5 with Vectofusin-1 (Miltenyi Biotec). After 3 days of cultivation, cells were collected and cultured in KGM on a regular 3T3-J2 feeder layer. Keratinocytes were treated with 2 μ g/mL of puromycin (Sigma) for 72 h, enabling the selection of cells. The selected sub-confluent transduced primary keratinocyte cultures were trypsinized and plated in over-confluent conditions to induce differentiation. Samples were feeder depleted and harvested at 3, 7, 10, and 14 days of culture.

3D SE culture preparation

3T3-J2 -populated collagen gels (final concentration of 5 mg/mL) were prepared as reported previously⁶⁸ and seeded with primary human keratinocytes (1 \times 10⁵ cells/scaffold) onto lethally irradiated 3T3-J2 cells (5 \times 10⁴ cells/scaffold) in KGM. After 6 days in submerged culture, the medium was removed, and the collagen gels were gently moved in Millicell cell culture (Merck). The 3D SE cultures were further cultured for 20–24 days in the air-liquid interface (ALI) condition to induce epidermal differentiation.

RNA extraction, real-time qPCR, and droplet digital PCR

Total RNA was isolated from cultured cells using the PureLink RNA Mini Kit (Thermo Fisher Scientific). cDNA was generated using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Real-time qPCR analyses were carried out on triplicate samples of retrotranscribed cDNA with TaqMan Universal PCR Master Mix (Thermo Fisher Scientific) on a 7900H Real-Time PCR System (Thermo Fisher Scientific).⁶⁹ Expression levels are given relative to human GAPDH. Data were analyzed using the 2^{- Δ Ct} quantification and visualized with Prism 8. Droplet digital PCR (ddPCR) was carried out for VCN evaluation on genomic DNA isolated from cultured cells using the QIAamp DNA Mini Kit (QIAGEN, 51304). Droplets were generated using the QX200 Droplet Generator (Bio-Rad) according to the manufacturer's instructions. PCR amplifications were performed in a thermal cycler and analyzed using a QX200 Droplet Reader (Bio-Rad). VCN was absolutely quantified considering an internal reference gene (VCN = 2). Data were analyzed using QuantaSoft Analysis Pro software and visualized with Prism 8. For both real-time qPCR and ddPCR, a list of TaqMan probes (Thermo Fisher Scientific) is provided in Table S2.

Western blotting

Samples of human primary keratinocytes destined for western blot analysis were depleted of feeder layer in 20 mM cold PBS/EDTA. Cells were lysed in 1 \times RIPA buffer (Sigma-Aldrich) supplemented with phosphatase and protease inhibitor cocktail (Thermo Fisher Scientific). BCA kits (Pierce) were used to quantify the total protein amount. Equivalent quantities of RIPA-solubilized proteins were resolved by 4%–12% NuPAGE BisTris gels or 10% NuPage Tris acetate gels (Thermo Fisher Scientific) at 100 V for 2 h and transferred to 100 V at 4°C for 2 h on a nitrocellulose membrane (Millipore). Membranes were treated with EveryBlot blocking buffer (Bio-Rad) for 5 min with agitation. Primary antibodies were diluted in blocking buffer as indicated in Table S3 and added overnight at 4°C to the membranes. Secondary antibodies were diluted in blocking buffer as indicated in Table S3 and added to the corresponding membranes for 1 h at room temperature. Signal was visualized with Clarity Western ECL Substrate (Bio-Rad) using ChemiDoc (Bio-Rad). Bio-Rad's Image Lab software 6.0 was used for band densitometry. A gray background on the images was homogeneously added for graphical purposes.

Immunofluorescence and H&E staining

For immunofluorescence analyses of *in vitro*-cultured keratinocytes, cells were plated at 1,000/well onto glass coverslips and grown as described previously. Cells were fixed with 3% paraformaldehyde (PFA) for 10 min at room temperature, carefully washed with 1 \times PBS, and permeabilized in 0.3% PBS/Triton for 15 min. Blocking solution (5% FBS and 2% BSA in 0.1% PBS/Triton) was added for 1 h at room temperature. Primary antibodies were diluted in blocking solution as described in Table S3 and added to the samples overnight at 4°C. Secondary antibodies were diluted in blocking solution as described in Table S3 and added to the samples for 1 h at room temperature. Cell nuclei were stained with DAPI. Dako

mounting medium was used to mount coverslips. A Carl Zeiss confocal microscope (LSM510meta) with a Carl Zeiss EC Plan-Neofluar 40×/1.3 oil immersion objective was used to visualize fluorescent signals.

For 3D human SE immunofluorescence, the 3D cultures were dehydrated in a sucrose gradient (0.9 M and 2 M) for 30 min at room temperature, embedded in Killik-OCT Cryostat Embedding Medium (Bio-Optica), and frozen. 7- μ m sections of embedded SE were obtained with a histological cryomicrotome (Leica CM1850 UV). Immunofluorescence was performed on 7- μ m cryosections. In brief, sections were fixed in 3% PFA or methanol, permeabilized for 15 min with 0.3% PBS/Triton, and blocked for 30 min at 37°C with blocking solution (5% BSA in PBS). The primary antibody, diluted in blocking solution, was added to skin sections for 2 h at 37°C. Sections were washed three times in wash solution (0.1% PBS/Triton) and incubated with secondary antibody diluted in blocking solution for 1 h at room temperature. Cell nuclei were stained with DAPI for 3 min at room temperature. Glasses were then mounted with Dako mounting medium, and fluorescent signals were monitored under a Carl Zeiss confocal microscope LSM900 with a Carl Zeiss EC Plan-Neofluar 40×/1.3 oil immersion objective. The antibodies used are described in Table S3.

H&E staining was performed on 7- μ m cryosections of 3D SEs (Harris hematoxylin for 1 min, running tap water for 1 min, eosin Y 50% in ethanol for 30 s, 95% ethanol for 1 min, 100% ethanol for 1 min, and two rinses in fresh 100% ethanol for 1 min each). Color bright-field images were taken with a Carl Zeiss microscope (Axio Imager M2) with an EC Plan-Neofluar 40×/0.75 M27 air objective.

Colony-forming efficiency assay

Colony-forming efficiency was calculated at each passage from the indicator dish stained with rhodamine B after 12 days of cultivation. The percentages of clonogenic cells correspond to the number of colonies on the total amount of plated cells; the percentage of abortive colonies was calculated as the number of abortive colonies among the total number of colonies.

Generation of the $\Delta TGM1$ human cellular model

gRNA CRISPR guides (Invitrogen) were designed to target *TGM1* E2 (gRNA1, 5'-AAATGCGGCAGATGACGACT-3' and gRNA2, 5'-AAATGCGGCAGATGACGACG-3'), which differ in 1 nt (underlined), allowing targeting of both *TGM1* alleles, exploiting the presence of a SNP in a wild-type strain [K81], and *TGM1* E4 (gRNA3, 5'-GGATGTAGATCTCATTGCGG-3'). gRNAs were checked for the minimal off-target activity predicted by an online tool (<http://www.rgenome.net/cas-offinder/>). gRNAs were mixed with the Cas9 protein (Alt-R S.p. Cas9 Nuclease V3, Integrated DNA Technologies [IDT], 1081058) in a 0.3:0.3:0.3:1 ratio and incubated at room temperature for 20 min, forming the RNP complex. 5×10^5 primary human keratinocytes (K81 strain) were resuspended in a final volume of 100 μ L of primary cell nucleofection solution (P3 Primary Cell 4D-Nucleofector Kit, Lonza), mixed with the RNP complex solution

and 4 mM Cas9 electroporation enhancer (IDT), and nucleofected using a 4D-Nucleofector (Lonza).⁷⁰

Genomic analysis by sequence decomposition (TIDE) of the $\Delta TGM1$ human cellular model

Genomic DNA isolated from $\Delta TGM1$ and non-treated keratinocytes was used for the screening of the *TGM1* sequence through PCR amplification. Two couples of primers (11-12 and 13-14; Table S2) were used to investigate the genomic sequence flanking both edited exons (e.g., E2 and E4, respectively). Moreover, PCR fragments spanning the Cas9 target sites were generated to evaluate the excision of the entire genomic region of above 1.7 kb between E2 and E4 with 11–14 primers (Table S2). PCR products were analyzed in 1% agarose gel. The molecular weight markers were the 100-bp DNA Ladder (Invitrogen) and 1-kb Plus DNA Ladder (Invitrogen). PCR amplicons were subjected to conventional Sanger sequencing. The resulting sequence trace files were uploaded on the TIDE web tool with the gRNA sequence as input. Obtained data were visualized with Prism 8.

Isolation of cross-linked cornified cell envelopes

For envelope formation, human primary keratinocytes were seeded onto a Millicell cell culture insert of 12-mm diameter with 0.4- μ m pore size (Merck) for 5 days in submerged culture and further cultured for 20–24 days in the ALI condition to induce epidermal differentiation. Thereafter, the insert was carefully removed with tweezers and submerged in a buffer solution consisting of 1 M Tris-HCl (pH 8.0), 2% 2-mercaptoethanol, and 2% SDS.³⁷ The suspension was heated to 100°C for 10 min and vortex mixed for 10 min. Envelope suspension was assessed by phase-contrast microscopy.

TG1 *in situ* enzymatic activity assay

TG1 *in situ* activity was performed on unfixed cryosections (7 μ m thick) as described previously.⁷¹ The 3D SE cryosections (from normal, $\Delta TGM1$, or SIN γ -RV-*TGM1*-transduced keratinocytes) were air dried for 10 min at room temperature and then blocked with 1% BSA in PBS for 30 min at room temperature. Sections were incubated in 100 mmol/L Tris-HCl (pH 7.4), 5 mmol/L CaCl₂, and 0.1 mmol/L Alexa Fluor 594 Cadaverine (A30678, Thermo Fisher Scientific) for 90 min at room temperature. Cell nuclei were stained with DAPI. Glasses were mounted with Dako mounting medium, and fluorescent images were obtained using a Carl Zeiss confocal microscope (LSM900) with a Carl Zeiss EC Plan-Neofluar 20×/0.50 M27 air objective.

TG1 *in vitro* enzymatic activity assay

The TG1 *in vitro* activity assay was performed with 50 μ g of protein extracts obtained from normal or $\Delta TGM1$ keratinocytes in growing (3-day) and over-confluent (14-day) conditions using the Transglutaminase Assay Kit (CS1070, Merck) according to the manufacturer's instructions. Briefly, 50 μ g of protein extracts was added to each well, and 2 milliunits/mL of transglutaminase enzyme from guinea pig liver was used as a positive control. 50 μ L of assay mixture was added to each well, and the plate was incubated for 30 min at room temperature. Streptavidin-peroxidase and TMB substrate were added

to each well, and the absorption was read at 450 nm with a plate-reading spectrophotometer (Glomax, Promega).

Encapsulation with the 10X Genomics chromium system and bioinformatics analysis on single-cell multiome data (ATAC and gene expression)

Fully confluent keratinocytes were detached, and cells were accurately resuspended to obtain a single-cell suspension in PBS containing 0.04% BSA. About 8×10^4 cells of SIN γ -RV-*TGMI*-transduced keratinocyte samples were subjected to nucleus isolation and DNA fragmentation according to the manufacturer's instructions (CG000338 Rev F, 10X Genomics). About 15,000 nuclei were loaded into the Chromium Next GEM Chip J using the Single Cell Multiome ATAC + Gene Expression Kit (10 \times Genomics). The sample was pre-amplified and half-divided to generate the Illumina sequencing ATAC and GEX libraries. Sequencing was performed on the NovaSeq6000 SP platform following the 10 \times Genomics instructions for read generation (150PE), reaching, on average, 67,000 reads per cell for the GEX library and 213,000 reads per cell for the ATAC library.

For the bioinformatics analysis, the Cell Ranger ARC pipeline (v.2.0.2) was used to generate FASTQ files, to align reads to the reference transcriptome (GRCh38) for the GEX library or to the reference genome (GRCh38) plus the exogenous SIN γ -RV-*TGMI* (provirus sequence) for the ATAC library, and to calculate unique molecular identifier counts from the mapped reads. The feature-barcode matrix was imported in R (v.4.2.2) and analyzed using the Seurat⁷² (v.4.3.0), Signac⁷³ (v.1.9.0), and popsicleR⁷⁴ (v.0.2.1) R packages. Low-quality cells were identified as outliers for both GEX and ATAC quality metrics and subsequently discarded. Doublets were identified and discarded using scDblFinder⁷⁵ (v.1.8.0). Cell cycle scores were assigned to each remaining cell and regressed out before dimensionality reduction with PCA on GEX data. Then, cells were clustered at low resolution to discriminate major cell populations. Cells were classified into holoclones, meroclones, paraclones, and terminally differentiated cells using an annotated scRNA-seq dataset of human keratinocytes^{43,44} as a reference and the FindTransferAnchors, TransferData, and MapQuery functions in Seurat with default parameters. Clusters representing fibroblasts were identified using the expression level of *VIM* and *COL1A1*. We assessed the quality of the assigned labels monitoring the expression of known markers. Finally, to identify transduced keratinocytes, we recovered, for each cell, the number of fragments mapped to the provirus sequence from the "ATAC Per Fragment Information" file generated by Cell Ranger ARC. Expression data are available in the Gene Expression Omnibus (GEO: GSE268321).

Statistical analyses

GraphPad Prism v.8 was used for statistical analyses in the main and supplemental figures. RT-qPCR data are presented as the mean \pm SD of at least three independent experiments ($n = 3$). Significance was calculated from Δ Ct values with ANOVA. A value of $p < 0.0001$ was considered statistically significant.

Replications

All experiments were replicated a number of times depending on the experiment performed. For qualitative data, such as those obtained from immunofluorescence, images are representative of what was observed in at least three independent samples or replicates.

DATA AND CODE AVAILABILITY

All data generated or analyzed during this study are available from the corresponding author upon reasonable request.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.omtm.2024.101311>.

ACKNOWLEDGMENTS

This project was supported by the European Union "National Center for Gene Therapy and Drugs based on RNA Technology" NextGenerationEU (PNRR) (mission 4, component 2, investment 1.4, CN 00000041, CUP E93C22001080001), European Research Council (ERC) advanced grant HOLO-GT (101019289), and Telethon (grant GGP20088). We thank Le Ali di Camilla for providing assistance to patients.

AUTHOR CONTRIBUTIONS

L.S. performed experiments, analyzed data, assembled all input data, and edited the manuscript. G.M. and E.E. contributed to the multiome experiment. O.R. and M.F. performed multiome bioinformatics analyses. L.D.R. and M.D.L. coordinated the study, defined strategic procedures, performed the experiments, and revised the manuscript.

DECLARATION OF INTERESTS

M.D.L. is a consultant for J-TEC-Japan Tissue Engineering, Ltd.

REFERENCES

- Elias, P.M., Williams, M.L., Crumrine, D., and Schmuth, M. (2010). Focuses solely on generalized, inherited (Mendelian) disorders of cornification (DOC or MeDOC). Introduction. *Curr. Probl. Dermatol.* 39, 1–29. <https://doi.org/10.1159/000321082>.
- Oji, V., Tadini, G., Akiyama, M., Blanchet Bardon, C., Bodemer, C., Bourrat, E., Coudiere, P., DiGiovanna, J.J., Elias, P., Fischer, J., et al. (2010). Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. *J. Am. Acad. Dermatol.* 63, 607–641.
- Fischer, J., and Bourrat, E. (2020). Genetics of Inherited Ichthyoses and Related Diseases. *Acta Derm. Venereol.* 100, adv00096. <https://doi.org/10.2340/00015555-3432>.
- Vahlquist, A., Fischer, J., and Törmä, H. (2018). Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. *Am. J. Clin. Dermatol.* 19, 51–66.
- Abernethy, J.L., Hill, R.L., and Goldsmith, L.A. (1977). epsilon-(gamma-Glutamyl) lysine cross-links in human stratum corneum. *J. Biol. Chem.* 252, 1837–1839.
- Rice, R.H., and Green, H. (1977). The cornified envelope of terminally differentiated human epidermal keratinocytes consists of cross-linked protein. *Cell* 11, 417–422.
- Takeichi, T., and Akiyama, M. (2016). Inherited ichthyosis: Non-syndromic forms. *J. Dermatol.* 43, 242–251.
- Fleckman, P., and DiGiovanna, J.J. (2012). Chapter 49. The Ichthyoses. In *Fitzpatrick's Dermatology in General Medicine*, 8e, L.A. Goldsmith, S.I. Katz, B.A. Gilchrist, A.S. Paller, D.J. Leffell, and K. Wolff, eds. (The McGraw-Hill Companies).

9. Schmuth, M., Martinz, V., Janecke, A.R., Fauth, C., Schossig, A., Zschocke, J., and Gruber, R. (2013). Inherited ichthyoses/generalized Mendelian disorders of cornification. *Eur. J. Hum. Genet.* *21*, 123–133.
10. Schmuth, M., Gruber, R., Elias, P.M., and Williams, M.L. (2007). Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. *Adv. Dermatol.* *23*, 231–256.
11. Arkin, L., Lee, L.W., Rubin, A.I., and Yan, A.C. (2015). Congenital Diseases (Genodermatoses). In *Lever's Histopathology of the Skin*, 11th Edition, D.E. Elder, ed.
12. Farasat, S., Wei, M.-H., Herman, M., Liewehr, D.J., Steinberg, S.M., Bale, S.J., Fleckman, P., and Toro, J.R. (2009). Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autosomal recessive congenital ichthyosis in the USA. *J. Med. Genet.* *46*, 103–111.
13. Simpson, J.K., Martínez-Queipo, M., Onoufriadis, A., Tso, S., Glass, E., Liu, L., Higashino, T., Scott, W., Tierney, C., Simpson, M.A., et al. (2020). Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis. *Br. J. Dermatol.* *182*, 729–737. <https://doi.org/10.1111/bjd.18211>.
14. Chulpanova, D.S., Shaimardanova, A.A., Ponomarev, A.S., Elsheikh, S., Rizvanov, A.A., and Solovyeva, V.V. (2022). Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis. *Int. J. Mol. Sci.* *23*, 2506.
15. Gutiérrez-Cerrajero, C., Sprecher, E., Paller, A.S., Akiyama, M., Mazereeuw-Hautier, J., Hernández-Martín, A., and González-Sarmiento, R. (2023). Ichthyosis. *Nat. Rev. Dis. Primers* *9*, 2. <https://doi.org/10.1038/s41572-022-00412-3>.
16. Aufenvenne, K., Larcher, F., Hausser, I., Duarte, B., Oji, V., Nikolenko, H., Del Rio, M., Dathé, M., and Traupe, H. (2013). Topical enzyme-replacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. *Am. J. Hum. Genet.* *93*, 620–630.
17. Plank, R., Yealand, G., Miceli, E., Lima Cunha, D., Graff, P., Thomforde, S., Gruber, R., Moosbrugger-Martinz, V., Eckl, K., Calderón, M., et al. (2019). Transglutaminase 1 replacement therapy successfully mitigates the autosomal recessive congenital ichthyosis phenotype in full-thickness skin disease equivalents. *J. Invest. Dermatol.* *139*, 1191–1195.
18. Freedman, J.C., Parry, T.J., Zhang, P., Majumdar, A., Krishnan, S., Regula, L.K., O'Malley, M., Coghlan, S., Yogesha, S.D., Ramasamy, S., and Agarwal, P. (2021). Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis. *J. Invest. Dermatol.* *141*, 874–882.e6.
19. Huber, M., Limat, A., Wagner, E., and Hohl, D. (2000). Efficient *in vitro* transfection of human keratinocytes with an adenovirus-enhanced receptor-mediated system. *J. Invest. Dermatol.* *114*, 661–666. <https://doi.org/10.1046/j.1523-1747.2000.00942.x>.
20. Mustafa, S.A., Maurizi, E., McGrath, J., and Chiappini, C. (2021). Nanomedicine approaches to negotiate local biobarriers for topical drug delivery. *Adv. Therapeut.* *4*, 2000160.
21. Choate, K.A., Kinsella, T.M., Williams, M.L., Nolan, G.P., and Khavari, P.A. (1996). Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes. *Hum. Gene Ther.* *7*, 2247–2253. <https://doi.org/10.1089/hum.1996.7.18-2247>.
22. Choate, K.A., Medalie, D.A., Morgan, J.R., and Khavari, P.A. (1996). Corrective gene transfer in the human skin disorder lamellar ichthyosis. *Nat. Med.* *2*, 1263–1267.
23. Choate, K.A., and Khavari, P.A. (1997). Direct cutaneous gene delivery in a human genetic skin disease. *Hum. Gene Ther.* *8*, 1659–1665. <https://doi.org/10.1089/hum.1997.8.14-1659>.
24. De Rosa, L., Enzo, E., Palamenghi, M., Sercia, L., and De Luca, M. (2023). Stairways to Advanced Therapies for Epidermolysis Bullosa. *Cold Spring Harbor Perspect. Biol.* *15*, a041229. <https://doi.org/10.1101/cshperspect.a041229>.
25. Hirsch, T., Rothoef, T., Teig, N., Bauer, J.W., Pellegrini, G., De Rosa, L., Scaglione, D., Reichelt, J., Klausegger, A., Kneisz, D., et al. (2017). Regeneration of the entire human epidermis using transgenic stem cells. *Nature* *551*, 327–332. <https://doi.org/10.1038/nature24487>.
26. Eichstadt, S., Barriga, M., Ponakala, A., Teng, C., Nguyen, N.T., Siprashvili, Z., Nazaroff, J., Gorell, E.S., Chiou, A.S., Taylor, L., et al. (2019). Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. *JCI Insight* *4*, e130554. <https://doi.org/10.1172/jci.insight.130554>.
27. Siprashvili, Z., Nguyen, N.T., Gorell, E.S., Loutit, K., Khuu, P., Furukawa, L.K., Lorenz, H.P., Leung, T.H., Keene, D.R., Rieger, K.E., et al. (2016). Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. *JAMA* *316*, 1808–1817. <https://doi.org/10.1001/jama.2016.15588>.
28. Kueckelhaus, M., Rothoef, T., De Rosa, L., Yeni, B., Ohmann, T., Maier, C., Eitner, L., Metzke, D., Losi, L., Secone Seconetti, A., et al. (2021). Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa - 5-Year Outcomes. *N. Engl. J. Med.* *385*, 2264–2270. <https://doi.org/10.1056/NEJMoa2108544>.
29. Lorand, L., and Graham, R.M. (2003). Transglutaminases: crosslinking enzymes with pleiotropic functions. *Nat. Rev. Mol. Cell Biol.* *4*, 140–156.
30. Deyrieux, A.F., and Wilson, V.G. (2007). *In vitro* culture conditions to study keratinocyte differentiation using the HaCaT cell line. *Cytotechnology* *54*, 77–83.
31. Wilson, V.G. (2014). Growth and differentiation of HaCaT keratinocytes. *Methods Mol. Biol.* *1195*, 33–41.
32. Barrandon, Y., and Green, H. (1987). Three clonal types of keratinocyte with different capacities for multiplication. *Proc. Natl. Acad. Sci. USA* *84*, 2302–2306.
33. Ronfard, V., Rives, J.M., Neveux, Y., Carsin, H., and Barrandon, Y. (2000). Long-term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. *Transplantation* *70*, 1588–1598.
34. Borowiec, A.-S., Delcourt, P., Dewailly, E., and Bidaux, G. (2013). Optimal differentiation of *in vitro* keratinocytes requires multifactorial external control. *PLoS One* *8*, e77507.
35. Poumay, Y., and Pittelkow, M.R. (1995). Cell density and culture factors regulate keratinocyte commitment to differentiation and expression of suprabasal K1/K10 keratins. *J. Invest. Dermatol.* *104*, 271–276.
36. Boeshans, K.M., Mueser, T.C., and Ahvazi, B. (2007). A three-dimensional model of the human transglutaminase 1: insights into the understanding of lamellar ichthyosis. *J. Mol. Model.* *13*, 233–246.
37. Jeon, S., Djian, P., and Green, H. (1998). Inability of keratinocytes lacking their specific transglutaminase to form cross-linked envelopes: absence of envelopes as a simple diagnostic test for lamellar ichthyosis. *Proc. Natl. Acad. Sci. USA* *95*, 687–690.
38. Chu, D.H. (2008). Chapter 7. Development and Structure of Skin. In *Fitzpatrick's Dermatology in General Medicine*, 7e, L.A. Goldsmith, K. Wolff, S.I. Katz, B.A. Gilchrist, A.S. Paller, and D.J. Leffell, eds. (The McGraw-Hill Companies).
39. Elias, P.M., Williams, M.L., Crumrine, D., and Schmuth, M. (2010). Inherited disorders of corneocyte proteins. *Curr. Probl. Dermatol.* *39*, 98–131. <https://doi.org/10.1159/000321086>.
40. Aufenvenne, K., Rice, R.H., Hausser, I., Oji, V., Hennies, H.C., Rio, M.D., Traupe, H., and Larcher, F. (2012). Long-term faithful recapitulation of transglutaminase 1-deficient lamellar ichthyosis in a skin-humanized mouse model and insights from proteomic studies. *J. Invest. Dermatol.* *132*, 1918–1921.
41. Hohl, D., Huber, M., and Frenk, E. (1993). Analysis of the cornified cell envelope in lamellar ichthyosis. *Arch. Dermatol.* *129*, 618–624.
42. Wiegmann, H., Valentin, F., Tarinski, T., Liebau, E., Loser, K., Traupe, H., and Oji, V. (2019). LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: Implications for targeted therapy of Netherton syndrome. *Br. J. Dermatol.* *181*, 999–1008.
43. Enzo, E., Secone Seconetti, A., Forcato, M., Tenedini, E., Polito, M.P., Sala, I., Carulli, S., Contin, R., Peano, C., Tagliafico, E., et al. (2021). Single-keratinocyte transcriptomic analyses identify different clonal types and proliferative potential mediated by FOXM1 in human epidermal stem cells. *Nat. Commun.* *12*, 2505. <https://doi.org/10.1038/s41467-021-22779-9>.
44. Polito, M.P., Marini, G., Fabrizi, A., Sercia, L., Enzo, E., and De Luca, M. (2024). Biochemical role of FOXM1-dependent histone linker H1B in human epidermal stem cells. *Cell Death Dis.* *15*, 508. <https://doi.org/10.1038/s41419-024-06905-1>.
45. Cortés, H., Del Prado-Audelo, M.L., Urbán-Morlán, Z., Alcalá-Alcalá, S., González-Torres, M., Reyes-Hernández, O.D., González-Del Carmen, M., and Leyva-Gómez, G. (2020). Pharmacological treatments for cutaneous manifestations of inherited ichthyoses. *Arch. Dermatol. Res.* *312*, 237–248. <https://doi.org/10.1007/s00403-019-01994-x>.

46. DiGiovanna, J.J., Mauro, T., Milstone, L.M., Schmuth, M., and Toro, J.R. (2013). Systemic retinoids in the management of ichthyoses and related skin types. *Dermatol. Ther.* 26, 26–38. <https://doi.org/10.1111/j.1529-8019.2012.01527.x>.
47. Fleckman, P., Newell, B.D., van Steensel, M.A., and Yan, A.C. (2013). Topical treatment of ichthyoses. *Dermatol. Ther.* 26, 16–25. <https://doi.org/10.1111/j.1529-8019.2012.01526.x>.
48. Chulpanova, D.S., Shaimardanova, A.A., Ponomarev, A.S., Elsheikh, S., Rizvanov, A.A., and Solovyeva, V.V. (2022). Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis. *Int. J. Mol. Sci.* 23, 2506. <https://doi.org/10.3390/ijms23052506>.
49. Joosten, M.D.W., Clabbers, J.M.K., Jonca, N., Mazereeuw-Hautier, J., and Gostyrński, A.H. (2022). New developments in the molecular treatment of ichthyosis: review of the literature. *Orphanet J. Rare Dis.* 17, 269. <https://doi.org/10.1186/s13023-022-02430-6>.
50. Dang, L., Zhou, X., Zhong, X., Yu, W., Huang, S., Liu, H., Chen, Y., Zhang, W., Yuan, L., Li, L., et al. (2022). Correction of the pathogenic mutation in TGM1 gene by adenine base editing in mutant embryos. *Mol. Ther.* 30, 175–183. <https://doi.org/10.1016/j.ymthe.2021.05.007>.
51. Ledford, H. (2023). Why CRISPR babies are still too risky - embryo studies highlight challenges. *Nature* 615, 568–569. <https://doi.org/10.1038/d41586-023-00756-0>.
52. Ginn, S.L., Amaya, A.K., Alexander, I.E., Edelstein, M., and Abedi, M.R. (2018). Gene therapy clinical trials worldwide to 2017: An update. *J. Gene Med.* 20, e3015. <https://doi.org/10.1002/jgm.3015>.
53. Chakravarti, S., Enzo, E., Rocha Monteiro de Barros, M., Maffezzoni, M.B.R., and Pellegrini, G. (2022). Genetic Disorders of the Extracellular Matrix: From Cell and Gene Therapy to Future Applications in Regenerative Medicine. *Annu. Rev. Genom. Hum. Genet.* 23, 193–222. <https://doi.org/10.1146/annurev-genom-083117-021702>.
54. Cavazza, A., Cocchiarella, F., Bartholomae, C., Schmidt, M., Pincelli, C., Larcher, F., and Mavilio, F. (2013). Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes. *Gene Ther.* 20, 949–957. <https://doi.org/10.1038/gt.2013.18>.
55. Kraunus, J., Schaumann, D.H.S., Meyer, J., Modlich, U., Fehse, B., Brandenburg, G., von Laer, D., Klump, H., Schambach, A., Bohne, J., and Baum, C. (2004). Self-inactivating retroviral vectors with improved RNA processing. *Gene Ther.* 11, 1568–1578. <https://doi.org/10.1038/sj.gt.3302309>.
56. Yi, Y., Hahm, S.H., and Lee, K.H. (2005). Retroviral gene therapy: safety issues and possible solutions. *Curr. Gene Ther.* 5, 25–35. <https://doi.org/10.2174/1566523052997514>.
57. Bauer, J.W., Koller, J., Murauer, E.M., De Rosa, L., Enzo, E., Carulli, S., Bondanza, S., Recchia, A., Muss, W., Diem, A., et al. (2017). Closure of a Large Chronic Wound through Transplantation of Gene-Corrected Epidermal Stem Cells. *J. Invest. Dermatol.* 137, 778–781. <https://doi.org/10.1016/j.jid.2016.10.038>.
58. De Rosa, L., Latella, M.C., Secone Seconetti, A., Cattelan, C., Bauer, J.W., Bondanza, S., and De Luca, M. (2020). Toward Combined Cell and Gene Therapy for Genodermatoses. *Cold Spring Harbor Perspect. Biol.* 12, a035667. <https://doi.org/10.1101/cshperspect.a035667>.
59. Mavilio, F., Pellegrini, G., Ferrari, S., Di Nunzio, F., Di Iorio, E., Recchia, A., Maruggi, G., Ferrari, G., Provasi, E., Bonini, C., et al. (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. *Nat. Med.* 12, 1397–1402. <https://doi.org/10.1038/nm1504>.
60. Oji, V., and Traupe, H. (2009). Ichthyosis. *Clinical Manifestations and Practical Treatment Options. Am. J. Clin. Dermatol.* 10, 351–364.
61. Kuramoto, N., Takizawa, T., Takizawa, T., Matsuki, M., Morioka, H., Robinson, J.M., and Yamanishi, K. (2002). Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1. *J. Clin. Invest.* 109, 243–250.
62. Matsuki, M., Yamashita, F., Ishida-Yamamoto, A., Yamada, K., Kinoshita, C., Fushiki, S., Ueda, E., Morishima, Y., Tabata, K., Yasuno, H., et al. (1998). Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). *Proc. Natl. Acad. Sci. USA* 95, 1044–1049.
63. Gálvez, V., Chacón-Solano, E., Bonafont, J., Mencía, Á., Di, W.L., Murillas, R., Llamas, S., Vicente, A., Del Rio, M., Carretero, M., and Larcher, F. (2020). Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome. *Mol. Ther. Methods Clin. Dev.* 18, 280–290. <https://doi.org/10.1016/j.omtm.2020.05.031>.
64. Dellambra, E., Vailly, J., Pellegrini, G., Bondanza, S., Golisano, O., Macchia, C., Zambruno, G., Meneguzzi, G., and De Luca, M. (1998). Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. *Hum. Gene Ther.* 9, 1359–1370. <https://doi.org/10.1089/hum.1998.9.9-1359>.
65. Enzo, E., Cattaneo, C., Consiglio, F., Polito, M.P., Bondanza, S., and De Luca, M. (2022). Clonal analysis of human clonogenic keratinocytes. *Methods Cell Biol.* 170, 101–116. <https://doi.org/10.1016/bs.mcb.2022.02.009>.
66. Phillips, M.A., Jessen, B.A., Lu, Y., Qin, Q., Stevens, M.E., and Rice, R.H. (2004). A distal region of the human TGM1 promoter is required for expression in transgenic mice and cultured keratinocytes. *BMC Dermatol.* 4, 2. <https://doi.org/10.1186/1471-5945-4-2>.
67. Ghazizadeh, S., Doumeng, C., and Taichman, L.B. (2002). Durable and stratum-specific gene expression in epidermis. *Gene Ther.* 9, 1278–1285. <https://doi.org/10.1038/sj.gt.3301800>.
68. Banerjee, N.S., Chow, L.T., and Broker, T.R. (2005). Retrovirus-mediated gene transfer to analyze HPV gene regulation and protein functions in organotypic "raft" cultures. *Methods Mol. Med.* 119, 187–202. <https://doi.org/10.1385/1-59259-982-6:187>.
69. Maurizi, E., Martella, D.A., Schirolli, D., Merra, A., Mustfa, S.A., Pellegrini, G., Macaluso, C., and Chiappini, C. (2022). Nanoneedles Induce Targeted siRNA Silencing of p16 in the Human Corneal Endothelium. *Adv. Sci.* 9, e2203257. <https://doi.org/10.1002/advs.202203257>.
70. Cattaneo, C., Enzo, E., De Rosa, L., Sercia, L., Consiglio, F., Forcato, M., Bicciato, S., Paiardini, A., Basso, G., Tagliafico, E., et al. (2024). Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells. *Mol. Ther.* 32, 372–383. <https://doi.org/10.1016/j.ymthe.2023.11.027>.
71. Takeda, M., Nomura, T., Sugiyama, T., Miyauchi, T., Suzuki, S., Fujita, Y., and Shimizu, H. (2018). Compound heterozygous missense mutations p. Leu207Pro and p. Tyr544Cys in TGM1 cause a severe form of lamellar ichthyosis. *J. Dermatol.* 45, 1463–1467. <https://doi.org/10.1111/1346-8138.14675>.
72. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888–1902.e21. <https://doi.org/10.1016/j.cell.2019.05.031>.
73. Stuart, T., Srivastava, A., Madad, S., Lareau, C.A., and Satija, R. (2021). Single-cell chromatin state analysis with Signac. *Nat. Methods* 18, 1333–1341. <https://doi.org/10.1038/s41592-021-01282-5>.
74. Grandi, F., Caroli, J., Romano, O., Marchionni, M., Forcato, M., and Bicciato, S. (2022). popsicleR: A R Package for Pre-processing and Quality Control Analysis of Single Cell RNA-seq Data. *J. Mol. Biol.* 434, 167560. <https://doi.org/10.1016/j.jmb.2022.167560>.
75. Germain, P.L., Lun, A., Garcia Meixide, C., Macnair, W., and Robinson, M.D. (2021). Doublet identification in single-cell sequencing data using scDblFinder. *F1000Res.* 10, 979. <https://doi.org/10.12688/f1000research.73600.2>.

OMTM, Volume 32

Supplemental information

A cellular disease model toward gene therapy of *TGM1*-dependent lamellar ichthyosis

Laura Sercia, Oriana Romano, Grazia Marini, Elena Enzo, Mattia Forcato, Laura De Rosa, and Michele De Luca




Figure S1. Time-resolved promoter activity by live-cell imaging of HaCaT cells transduced with SIN γ -RVs. Representative bright-field and fluorescent micrographs of HaCaT cells transduced with three different promoters, from top to bottom: the 2.2-Kb human TGM1 full length promoter (TGM1^{full}), the 367-bp human TGM1 minimal promoter (TGM1^{min}), the 637-bp human Involucrin minimal promoter (IVL^{min}), grown in high calcium medium for 6 days. n=3, pictures are representative of what was observed in at least three independent samples or replicates. Scale bars, 50 μ m.




Figure S2. TGM1^{min} and IVL^{min} promoters activity in keratinocytes. A) Western blot analysis of keratinocyte differentiation markers (IVL and endogenous TG1) and EGFP in growing (3d), confluent (7-10d) and over-confluent (14d) K28 keratinocytes transduced with (left) a SIN γ -RV carrying EGFP under the control of TGM1^{min} promoter or, (right) a SIN γ -RV carrying EGFP under the control of IVL^{min} promoter. B) EGFP mRNA expression during transgenic keratinocyte differentiation (3d-14d). GAPDH mRNA was used to normalize the qRT-PCR (* p < 0.0001). C) Representative immunofluorescent images of 7 μ m-thick cryosections of 3D skin equivalents obtained with TGM1^{min} or IVL^{min} promoter-transduced keratinocytes showing the EGFP fluorescent signal. White dotted line marks the epidermal-dermal junction. Scale bars 20 μ m.




Figure S3. Genotype of $\Delta TGM1$ cellular model. A) Top: *TGM1*-knockout strategy design. gRNA1 and gRNA2 target Exon 2, exploiting the presence of an SNP in a wild-type strain (K81), while gRNA3 targets Exon 4 of the *TGM1* gene. If the three cutting events occur simultaneously the resulting *TGM1* gene should be shorter as depicted in figure. Bottom: PCR analysis of genomic DNA from wild-type and $\Delta TGM1$ keratinocytes (K81), spanning both the Cas9 target sites to evaluate the excision of the 1.7 Kb genomic region between Exon 2 and Exon 4. Note that the excision of the entire genomic region is a high frequency event. B) TIDE decomposition analysis through Sanger sequencing of edited genomic sequences in $\Delta TGM1$ keratinocytes (K81) with gRNA1/2 (editing *TGM1*-E2) and gRNA3 (editing *TGM1*-E4) showing the overall editing efficiencies and the percentage of indel formation (insertions and deletions) in both edited exons, as compared to a wild-type sequence. The overall editing efficiencies, reaching 100%, is indicated by the absence of non-edited sequences (point 0 of the graphs) and the presence of a significant amount of InDels abolishing the open reading frame and expression of *TGM1*.




Figure S4. TG1 expression in $\Delta TGM1$ keratinocytes cultures at increased cell densities. A) SIN γ RV vector expressing *TGM1* cDNA under the control of its own promoter (SIN γ -RV-*TGM1*). B) Western blot analysis of exogenous TG1 (eTG1) and IVL differentiation marker in growing (3d), confluent (7-10d) and over-confluent (14d) keratinocytes transduced with SIN γ -RV-*TGM1*. n=3, picture is representative of what was observed in at least three independent replicates.




Figure S5. Vector Copy Number (VCN) of transduced HaCaT clones and keratinocytes cultures. ddPCR analysis of EGFP (green) and exogenous *TGM1* (red) Vector Copy Number in HaCaT clones (right) and bulk K82 keratinocytes (left) transduced with SIN γ -RV carrying TGM1^{min}, TGM1^{full} or IVL^{min} promoters. For the exogenous *TGM1* (red) VCN evaluation was used a custom probe design to recognize the provirus integration, that binds an exon-exon junction. VCN was absolutely quantified considering an internal reference gene (hGAPDH, VCN=2), n=2. Dots represent the single values, while middle line represents the mean value.




Figure S6. Single-cell multiomic analysis of *TGMI*-transduced keratinocytes. A) DotPlot showing the expression of clonogenic, holoclone and differentiation markers in the five SIN γ -RV-*TGMI* keratinocytes populations. Dots size indicates the percentage of cells expressing that gene, the average expression color scale refers to scaled data. B) Percentages of positive cells (bold), containing at least one provirus fragment and negative cells, without provirus integration, for each keratinocytes population. C) Number of SIN γ -RV-*TGMI* provirus fragments retrieved in individual cells, for each keratinocytes population.

Table S1. List of primers used with specified name, sequence, and application.

	Primer name	Sequence (5'-3')	Application	Notes
#1	TGM1 PromP1_F	ACCTAGTTAACGCTGAGTGTCTGCTCCCAT G	PCR amplification	distal region (-1.6 Kb / -1.4 Kb)
#2	TGM1 PromP1_R	TACAGGGCCGGCCTCCCAGAGAACCAGTA GGATG	PCR amplification	
#3	TGM1 PromP2_F	ATTCTGGCCGGCCTGCTCCCTCCCTAGC	PCR amplification	proximal region (90 bp / +67 bp)
#4	TGM1 PromP2_R	GATTTCCATGGTCAGGATGGATGGGAC	PCR amplification	
#5	IVL PromP1_F	TTGGGTAAACAGCTTCTCCATGTGTCATG	PCR amplification	distal region (- 2.473 Kb / -2.036 Kb)
#6	IVL PromP1_R	GAAGGCCGGCCGGTCTTATGGGTTAGC	PCR amplification	
#7	IVL PromP2_F	ATTAGGCCGGCCAGGAATAGTTGAGCTAC CAG	PCR amplification	proximal region (221 bp / +6 bp)
#8	IVL PromP2_R	GAAATCCATGGTGCTGAGCTGAGCAGGAG	PCR amplification	
#9	TGM1 ^{full} Prom_F	AAC TAGTTAACGCCAAGGCTTCAGTGTTT G	PCR amplification	full length promoter (2.2 Kb)
#10	TGM1 ^{full} Prom_R	ATTATGGCCGGCCGAGGTCTGGGGGCTTA GG	PCR amplification	
#11	TGM1_Exon2_F	GATGGGCCACGTTCCGATG	KO analysis	
#12	TGM1_Exon3_R	CGGGACAGGAGGAGGAGC	KO analysis	
#13	TGM1_Intron3_F	CAGTGGCTCATAACATTGTG	KO analysis	
#14	TGM1_Exon5_R	CTGCCGCCAATCCTCATGG	KO analysis	

Table S2. List of TaqMan® probes used for qRT-PCR and catalog number.

TaqMan® probes	Company	Catalog number
EGFP	Thermo Fisher	Mr00660654_cn
GAPDH	Thermo Fisher	4352665
Genomic GAPDH	Thermo Fisher	Hs03929097_g1
K10	Thermo Fisher	Hs00166289_m1
TGM1 Exon 14-15	Thermo Fisher	Hs00165929_m1
Exogenous TGM1	Thermo Fisher	Custom made

Table S3. List of antibodies, source, and concentration.

Antibody information				Dilution/amount	
Antibody	Company	Catalog number	Description	WB	IF
anti-TGM1	Invitrogen	PA5-59088	Rabbit polyclonal	1/1000 - 1/4000	
anti-TGM1	Merk	HPA040171	Rabbit polyclonal		1/2000
anti-Cytokeratin 14	BioLegend	905301	Rabbit polyclonal		1/150,000
anti-Collagen XVIIA1	Genetex	GTX54647	Mouse monoclonal		1/100
anti-SPINK5	Merk	HPA011351	Rabbit polyclonal		1/2000
anti-human GAPDH	Merk	ZRB374 - clone 10B13	Rabbit monoclonal	1/1000	
anti-GAPDH	Abcam	ab8245	Mouse monoclonal	1/10,000	
anti-Involucrin	Leica	NCL-INV	Mouse monoclonal	1/2000	1/1000
Anti-Loricrin	Abcam	Ab240187	Rabbit monoclonal		
anti-Cytokeratin 10	BioLegend	905403	Rabbit polyclonal	1/500	1/1000
anti-GFP	Santa Cruz Biotechnology	sc-9996	Mouse monoclonal	1/250	
anti-GFP	Merk	AB10145	Rabbit polyclonal	1/1000	1/500
anti-Vimentin	BioLegend	699302	Rat		1/1000
Alexa Fluor 568 anti-rat	Thermo Fisher Scientific	A11077	secondary antibody		1/1000
Donkey anti-rabbit IgG HRP	Santa Cruz Biotechnology	sc-2313	secondary antibody	1/2000	
Donkey anti-mouse IgG HRP	Santa Cruz Biotechnology	sc-2314	secondary antibody	1/10,000 - 1/20,000	
Donkey anti-Mouse IgG (H+L) Alexa Fluor 568	Thermo Fisher Scientific	A10037	secondary antibody		1/2000 - 1/1000
Donkey anti-Rabbit IgG (H+L) Alexa Fluor 488	Thermo Fisher Scientific	A21206	secondary antibody		1/2000 - 1/1000